Nilotinib

Nilotinib is an oral anticancer medicine belonging to the tyrosine kinase inhibitor class. It primarily blocks the BCR-ABL protein, an abnormal enzyme produced by cells carrying the Philadelphia chromosome. This genetic abnormality is associated with chronic myeloid leukemia (CML), a blood cancer in which abnormal white blood cells multiply excessively. By inhibiting BCR-ABL signalling, nilotinib helps reduce the growth and survival of leukaemia cells. It is used to treat Philadelphia chromosome-positive CML in the chronic phase in eligible adults and children, and certain adults with disease that has not responded adequately to, or cannot tolerate, previous treatment such as imatinib. Specific age groups and indications depend on the locally approved product information. Nilotinib is supplied as oral capsules and is generally taken twice daily on an empty stomach because food can increase its absorption and affect safety. Treatment requires specialist supervision because the medicine can affect heart rhythm, blood counts, liver function, blood glucose, and electrolyte levels. Molecular testing, electrocardiograms, laboratory assessments, and review of other medicines are important parts of care. The treatment plan depends on the patient's age, disease phase, previous therapy, response, and tolerance.

Nilotinib was developed as a targeted inhibitor of BCR-ABL tyrosine kinase to treat Philadelphia chromosome-positive CML. Its clinical development included studies comparing it with imatinib in newly diagnosed patients and studies evaluating its activity in patients whose disease was resistant to or who could not tolerate prior therapy. The United States Food and Drug Administration (FDA) first approved nilotinib in October 2007 for adults with chronic-phase or accelerated-phase Philadelphia chromosome-positive CML resistant to or intolerant of previous treatment that included imatinib. In June 2010, the FDA expanded its use to newly diagnosed adults with chronic-phase disease. The European Commission authorised Tasigna in the European Union on 19 November 2007. Subsequent regulatory updates extended eligible uses to paediatric patients in specified age groups and treatment settings. The ENESTnd clinical trial programme provided important evidence for first-line treatment. Approval details, paediatric eligibility, and available formulations vary by country, so current local prescribing information should be consulted.

Nilotinib is used to treat Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), a condition characterised by the presence of the Philadelphia chromosome in leukaemia cells. Approved uses include newly diagnosed chronic-phase CML in eligible adults and children, and chronic-phase or accelerated-phase CML in certain patients who are resistant to or intolerant of previous treatment, including imatinib. Paediatric indications and age requirements depend on the specific regulatory approval. Nilotinib works as a targeted therapy by inhibiting BCR-ABL tyrosine kinase rather than acting as a conventional cytotoxic chemotherapy medicine. Treatment selection is based on disease phase, previous treatment, molecular findings, age, and individual clinical factors. Nilotinib is not generally used as the standard treatment for CML in blast crisis because efficacy data for this setting are limited. Molecular monitoring helps assess response and determine whether the treatment remains effective.

Nilotinib is administered orally as capsules, generally twice daily at approximately 12-hour intervals. Under the US prescribing information, the usual adult dose for newly diagnosed chronic-phase Ph+ CML is 300 mg twice daily, while the usual adult dose for chronic-phase or accelerated-phase disease resistant to or intolerant of previous therapy is 400 mg twice daily. Paediatric dosing is calculated according to body surface area and must follow the applicable product information. Nilotinib must be taken on an empty stomach, with no food for at least two hours before each dose and one hour afterwards, because food can increase drug exposure and the risk of adverse effects. Treatment is usually continued while clinical benefit persists and toxicity remains acceptable. Dose interruption or reduction may be necessary for abnormal blood counts, liver abnormalities, QT prolongation, or other significant adverse effects. Treatment discontinuation may be considered for selected patients who achieve a sustained deep molecular response and meet the applicable criteria, but this requires specialist supervision and frequent molecular monitoring.

Common side effects of nilotinib include headache, nausea, rash, itching, fatigue, muscle pain, upper abdominal discomfort, and hair loss. Blood tests may show reduced platelet or neutrophil counts, increased bilirubin, or elevated liver and pancreatic enzymes. Some patients may develop increased blood glucose or cholesterol levels. The severity and pattern of side effects vary between individuals and may depend on the dose, treatment duration, and underlying health conditions. Regular laboratory testing helps identify abnormalities before they become clinically significant. Patients should inform their healthcare professional about persistent abdominal pain, worsening fatigue, unusual bruising, or other new symptoms. Side effects may require supportive treatment, closer monitoring, or adjustment of the prescribed dose.

Nilotinib carries an important warning for QT interval prolongation, which can cause potentially life-threatening heart rhythm disturbances and has been associated with sudden deaths. The medicine should not be used in patients with certain serious electrolyte abnormalities or congenital long QT syndrome, and ECG monitoring is required. Other serious risks include reduced blood-cell counts, liver toxicity, pancreatitis, and cardiovascular complications such as arterial occlusive events. These cardiovascular events can affect blood vessels supplying the heart, brain, or limbs. Patients may also experience significant changes in blood glucose or lipid levels. Severe abdominal pain, fainting, palpitations, chest pain, sudden weakness, or symptoms suggestive of a stroke require urgent medical assessment. Treatment may need to be withheld, reduced, or discontinued depending on the type and severity of the reaction. Patients should not change or stop treatment without consulting their treating specialist unless emergency medical personnel advise otherwise.

Before starting nilotinib, clinicians should review cardiovascular history, liver function, blood counts, electrolyte levels, blood glucose, lipid profile, and all current medicines. An ECG should be obtained before treatment, repeated approximately seven days after initiation, and repeated periodically and after relevant dose adjustments, according to prescribing guidance. Low potassium or magnesium levels should be corrected before treatment and monitored during therapy. Strong CYP3A4 inhibitors can increase nilotinib exposure, while strong CYP3A4 inducers may reduce its effectiveness. Other medicines that prolong the QT interval should generally be avoided when possible because of the risk of serious arrhythmias. Grapefruit and grapefruit products should be avoided because they may increase drug exposure. Patients with liver impairment may require a different starting dose or additional monitoring. Pregnancy and breastfeeding require careful specialist assessment, and effective contraception should be discussed because nilotinib may harm an unborn baby. Patients should consult their healthcare professional before starting any new prescription medicine, over-the-counter product, or herbal supplement.

Confirm Philadelphia chromosome-positive CML through appropriate diagnostic testing and establish the disease phase and treatment history before prescribing nilotinib. Obtain baseline ECG, blood counts, liver function tests, electrolytes, glucose, and lipid measurements. Correct potassium and magnesium abnormalities and review concurrent medicines for CYP3A4 interactions and QT-prolonging effects. Explain the fasting administration requirements clearly, including the two-hour period without food before a dose and the one-hour period afterwards. Reinforce adherence to the prescribed twice-daily schedule and advise patients not to double a missed dose. Monitor BCR-ABL transcript levels using standardised molecular testing to assess response and identify possible treatment failure. Review cardiovascular risk factors throughout therapy and manage diabetes, dyslipidaemia, hypertension, and smoking where relevant. Patients considering treatment-free remission should meet established eligibility criteria and undergo frequent molecular monitoring under specialist supervision. Ensure that any dose interruption, reduction, or restart follows the current product information and is coordinated with the treating haematology team.